CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])
CERE-120-02
Phase 2 small_molecule completed
Quick answer
CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) for Idiopathic Parkinson's Disease is a Phase 2 program (small_molecule) at SANGAMO THERAPEUTICS, INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- SANGAMO THERAPEUTICS, INC
- Indication
- Idiopathic Parkinson's Disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed